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Objectives: Public and private healthcare systems in Brazil differ in focus and 
regulations for disease management, especially mental health. The aim of this 
study was to assess differences between privately and publicly insured patients in 
access to care, as well as differences in mental health, work productivity impair-
ment, and healthcare resource utilization among patients diagnosed with depres-
sion. MethOds: The 2014 Brazil National Health and Wellness Survey (N= 9,082), 
a self-reported, cross-sectional survey representative of the adult population, 
provided data. Access outcomes included physician diagnosis of depression, 
visits to psychiatrists, and visits to psychologists in the past six months. Other 
outcomes included work impairment due to health using the Work Productivity 
and Activity Impairment questionnaire and depression severity according to the 
Patient Health Questionnaire. Patients with private insurance were compared to 
patients with only public insurance with chi-square tests; generalized linear mod-
els were used to adjust outcomes for covariates. Results: Overall, 11% (n= 990) 
of the sample reported a depression diagnosis. Diagnosis was more common 
among those with private than public insurance (12.5% vs. 9.3%, p< 0.001), a pat-
tern that remained after controlling for covariates (OR= 1.4, p< 0.001). Visiting a 
psychiatrist (OR= 1.7) or a psychologist (OR= 1.8) was also more common with 
private insurance (both p< 0.001). Among those diagnosed with depression, sever-
ity was lower among those with private insurance (mean 10.8 vs. 11.9, p= 0.026). 
Employed patients with depression with private insurance missed more work 
due to health (14.3% vs. 8.0%, p< 0.01), while the levels of health-related impair-
ment while at work, overall work impairment, and activity impairment were not 
significantly different. cOnclusiOns: Private insurance appears to be associated 
with more access to depression care as well as less severe depression among 
depression patients. More work missed among privately insured patients warrants 
further study, and may be due to differences not included here, such as type of 
employment.
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ObjectivOs: Estimar el uso de recursos médicos en la intervención de exámenes 
de tamizaje y tratamiento de pacientes con problemas y trastornos de salud mental 
2012-2013 MetOdOlOgíAs: Se utilizó la metodología de uso de recursos médicos 
en referencia al recurso humano, materiales e insumos médicos, medicamentos 
y equipamiento; considerando la asignación presupuestal en la intervención de 
exámenes de tamizaje y tratamiento de pacientes con problemas y trastornos 
de salud mental 2012-2013. en el ámbito de Presupuesto por Resultados (PpR). 
Contrastándose el uso de recursos médicos versus el indicador de desempeño del 
programa: Violencia familiar tomado de la Encuesta de Demografía y salud familiar 
(ENDES) 2012-2013. ResultAdOs: El uso de recursos humano en la intervención del 
2012- 2013 aumento de US$ 1,341,478 a US$1,796,384, el material e insumo medico 
disminuyo de US$134,302 a US$70,466, en medicamentos disminuyó de US$54,015 
a US$12,899, en equipos disminuyo de US$40,440 a US$1,126, Para el año 2012 el 
Porcentaje de Mujeres que sufrieron agresión física fue de 12.9, Para el año 2013 
Porcentaje de Mujeres que sufrieron agresión física fue de 12.1 cOnclusiOnes: 
La priorización en el presupuesto del uso de recurso humano en la intervención de 
exámenes de tamizaje y tratamiento de pacientes con problemas y trastornos de 
salud mental 2012-2013 ha tenido buenos resultados por lo que se debe tener mejor 
calidad de gasto en este recurso
PMH12
costs of relaPse of scHizoPHrenia for coloMbian HealtH sYsteM
Cordoba R1, Tellez D2, Garcia C3, Pavan E3
1Grupo Cisne, Bogota, Colombia, 2Janssen Cilag S.A., Bogotá, Colombia, 3Deloitte Consulting, 
Buenos Aires, Argentina
Schizophrenia is a chronic, severe, and disabling mental disorder that significantly 
affects a person’s thought processes and emotional responsiveness. People with 
schizophrenia have a relatively high utilization rate of health care and mental 
health services.Objectives: To quantify the cost of schizophrenia relapse in 
Colombia from the perspective of the third payer. MethOds: A cost of disease 
study was performed including direct, indirect and transference costs of relapses 
in schizophrenia. Bottom-up and top down methodologies were used to obtain 
direct costs consumed by this population. Validation of clinical criteria took place 
with local KOLs for epidemiological data and resoureces estimation. Burden of 
disease was calculated using Disability Adjusted Life Years. The impact on the local 
economy was also included by obtaining transference costs. Results: There is an 
estimation of 714,927 people living with schizophrenia in Colombia. The preva-
lence rate is 1.5%. Compared to other chronic conditions, onset of schizophrenia 
typically occurs at between 20 and 30 years. This study estimated that a total of 
150.135 patients experienced some episodes of relapse in 2014. This corresponds 
to 21% of patients with schizophrenia. This study found that the total potential 
avoidable direct healthcare costs of relapse in Colombia were COP$ 145´425.137 
(US$66, 1 million). Total indirect costs were estimated to be COP $ 28.882 million 
(US$ 13.1 million) over a 12 month period. There were 5.540 people not employed 
due to relapse which resulted in a loss of productivity of $COP 27.499 million (US$ 
desde la perspectiva del financiador tomados para el año 2014. La definición de 
los esquemas de manejo clínico (procedimientos médicos y medicamentos para 
el diagnóstico, tratamiento y seguimiento de la enfermedad) provienen de las 
Condiciones Asegurables del Plan Esencial de Aseguramiento en Salud (PEAS). 
Cada esquema de manejo clínico se ha estimado con la metodología de costeo 
estándar. El costo total fue ajustado por factores de oferta, demanda y adheren-
cia. ResultAdOs: La cohorte hipotética de pacientes con enfermedades mentales 
prevalentes (EMP) es de 75,584 (Incidencia esquizofrenia: 1%, incidencia de ansie-
dad: 19.5%, incidencia de depresión: 9% e incidencia de alcoholismo: 11.6%). El 
costo total para EMP es de 21,893,108 dólares distribuido según enfermedad para 
esquizofrenia 3,356,030 dólares (15%), ansiedad 2,040,292 dólares (9%); depresión 
12,621,897 dólares (58%) y para alcoholismo 3,874,889 (18%). El costo total corre-
spondiente a prevención es 943,888 dólares (4.3%), diagnóstico 1,771,448 dólares 
(8.1%), tratamiento 15,030,859 dólares (68.7%) y para seguimiento 4,146,913 dólares 
(18.9%). El costo fijo correspondió a 10,160,137 dólares (46.4%) y el costo variable 
a 11,732,971 dólares (53.6%). cOnclusiOnes: El costo anual total para enferme-
dades mentales prevalentes en el país se estimó en 21,893,108 dólares. Este monto 
representa el 91.3% del presupuesto asignado 2015 del Programa Presupuestal 131 
Control de Enfermedades Mentales.
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ObjectivOs: El seguimiento farmacoterapéutico (SFT) es una tecnología en salud, 
en la cual un profesional farmacéutico se responsabiliza de las necesidades del 
paciente para contribuir al logro de mejores resultados farmacoterapéuticos posi-
bles. Propósito para el cual el método Dáder ha sido ampliamente utilizado. El 
objetivo de este estudio fue realizar un análisis costo efectividad del efecto del 
método Dáder de SFT en pacientes con Trastorno Afectivo Bipolar (TAB I), usando 
la perspectiva del tercer pagador en Colombia. MetOdOlOgíAs: Análisis de 
costo/efectividad del SFT en pacientes con TAB I, comparado con el tratamiento 
convencional. Perspectiva: tercer pagador en Colombia. Horizonte temporal: 1 
año. Se construyó un árbol de decisión, con las probabilidades de recaída y los 
costos asociados de las dos alternativas evaluadas: la atención convencional y 
la adición del SFT. Los datos de efectividad se tomaron directamente del ensayo 
clínico randomizado EMDADER-TAB-I, específicamente se utilizó como medida 
efectividad la probabilidad de mantener al paciente eutímico durante un año. 
El macrocosteo se realizó con información del mercado y de bases de datos uti-
lizadas como referencia en Colombia. ResultAdOs: Los resultados del modelo 
indican que el SFT es una estrategia dominante sobre la atención convencional, 
siendo menos costosa (delta costos directos – 58.35 U$) y más efectiva (delta de 
efectividad 0,1518). Se pueden generar ahorros para el sistema de 396.95 U$ al 
año por paciente con TAB. Se realizaron dos análisis de sensibilidad; el primero 
determinístico de una vía, con el costo del SFT como variable incertidumbre y el 
segundo probabilísticos de todo el modelo. Se confirmó la robustez de los resul-
tados. cOnclusiOnes: El SFT, como tecnología que se adiciona a la atención 
habitual, resultó ser costo efectivo desde la perspectiva del tercer pagador. La dismi-
nución de las recaídas y por ende de las hospitalizaciones ofrece un ahorro para el 
sistema.
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Objectives: The World Health Organization estimates that depression affects 350 
million people worldwide and is the leading cause of disability. Although effica-
cious and cost-effective treatments are available, non-adherence is common and 
one of the most significant issues for successful treatment. Medication-adherent 
patients have almost three times greater odds for positive outcomes than patients 
with low adherence; poor adherence leads to quality of life decrements, mental 
health deterioration and increased costs, with indirect cost as the major impacting 
cost. Due to a lack of Brazilian data, this study investigates the association between 
adherence and burden of depression in the Brazilian population. MethOds: Data 
were from the 2011-2012 Brazil National Health and Wellness Survey (NHWS), 
an internet-based survey from a representative sample of adults stratified by 
age and gender. Out of 24,000 respondents, 2,760 (12%) reported a diagnosis of 
depression and 1,487 (6%) having a prescription medication for depression (Rx). 
Adherent respondents – high/medium adherence on the Morisky Medication 
Adherence Scale (MMAS-4) – were compared to the non-adherent on severity 
(PHQ-9), sociodemographics, health characteristics, health-related quality of life 
(SF-36), work productivity and activity impairment (WPAI) and healthcare resource 
use (physician, hospital and emergency visits). Results: Non-adherent respond-
ents (79%), compared to adherent respondents, were more severe (22% vs. 17% 
with PHQ-9 score ≥ 15); had lower Mental Component Summary (MCS: 33 vs. 36); 
lower health utilities (SF-6D: 0.59 vs. 0.60); higher presenteeism (42 vs. 37); and 
their satisfaction with medication was lower (4.9 vs. 5.3) (All p< 0.05). About 33% 
of both groups were participating in psychotherapy and showed no significant 
difference in Physical Component Summary (PCS); absenteeism; and healthcare 
resource use. cOnclusiOns: In this real-world study for Brazilian patients with 
depression, adherence demonstrated an important relationship on patients’ out-
comes to medication satisfaction and productivity, being an important key to 
successful treatment.
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Objectives: Pneumococcal disease is a public health concern worldwide. This study 
evaluates the public health and economic impact of 13-valent pneumococcal con-
jugate vaccine (PCV13) vaccination in Brazilian adults aged ≥ 50 years. MethOds: 
A cohort model with a Markov-type process depicting expected risk, consequences 
and costs of pneumococcal disease was developed. PCV13 effectiveness was based 
on data from CAPiTA; the 23-valent polysaccharide vaccine (PPSV23) effectiveness 
was based on published literature. Pneumococcal disease rates were based on data 
from DATASUS. Outcomes, direct and indirect costs (in BRL) were evaluated from a 
Brazilian public (n= 20,228,045) and private (n= 11,396,682) payer perspective over 
a 5 year time horizon. Results: From a public payer perspective, vaccination with 
PCV13 versus PPSV23 avoided 676,031 PD cases, 853 deaths with BRL 2,32 million 
cost saving. An expected 696.970 PD cases and 29.644 deaths would be avoided for 
PCV13 versus no vaccine 2,16 million cost savings. From a private payer perspec-
tive, vaccination with PCV13 versus PPSV23 avoided 410,302 PD cases and 1,074 
deaths with a 1.27million cost-savings. An expected 420,159 PD cases and 18,482 
deaths would be avoided for PCV13 versus no vaccine with a 1.69 million cost-
savings. cOnclusiOns: PCV13 prevents more pneumococcal disease cases and 
deaths than PPSV23 or no vaccine and is expected to save economic resources (direct 
and indirect) from a private perspective, and cost-effective from a public perspective.
Prs5
costo De tuberculosis en los estableciMientos De saluD Del Perú
Timana-Ruiz R1, Sobrevilla-Ricci A2, Mosqueira-Lovón R2, Gutierrez-Aguado A3,  
Escobedo-Palza S4
1SOMPEGS, Lima, Peru, 2Abt Associates-HFG Peru, Lima, Peru, 3UNMSM, Lima, Peru, 4SPEAS, 
Lima, Peru
ObjectivOs: Estimar los costos de la Tuberculosis (TBC) en los establecimien-
tos del Ministerio de Salud del Perú. MetOdOlOgíAs: Se realizó una evaluación 
económica parcial de tipo costo de enfermedad (CE). La población de estudio fue 
una cohorte hipotética de pacientes afiliada al Seguro Público de Salud (Seguro 
Integral de Salud) en el Perú. Los costos se estimaron desde la perspectiva del 
financiador tomados para el año 2014. La definición de los esquemas de manejo 
clínico (procedimientos médicos y medicamentos para el diagnóstico, tratami-
ento y seguimiento de la enfermedad) provienen de las Condiciones Asegurables 
del Plan Esencial de Aseguramiento en Salud (PEAS). Cada esquema de manejo 
clínico se ha estimado con la metodología de costeo estándar. El costo total 
fue ajustado por factores de oferta, demanda y adherencia. ResultAdOs: La 
cohorte hipotética de TBC es de 13,808 personas para el año 2014 (Incidencia 
de TBC Pulmonar: 0.11%, incidencia de TBC Extrapulmonar: 0.02%, incidencia 
de TBC con complicaciones: 0.01%, incidencia de TBC Multidrogoresistente: 
0.0036%). El costo total para TBC es de 27,443,865 dólares correspondiendo 
para TBC Pulmonar 23,666,252 dólares, TBC Extrapulmonar 1,501,742 dólares, 
TBC con complicaciones 935,552 dólares y para TBC Multidrogoresistente es 
de 1,340,319 dólares. El costo total correspondiente a diagnóstico es 1,302,884 
dólares (4.7%), tratamiento 24, 205,776 dólares (88.2%) y para seguimiento 1,935,206 
dólares (7.1%). El costo fijo correspondió a 12,538,706 dólares (45.7%) y el costo 
variable a 14,905,159 dólares (54.3%). cOnclusiOnes: El costo anual total para 
Tuberculosis en el Perú se estimó en 27,443,865 dólares. Este monto representa 
el 14.1% del presupuesto ejecutado el año 2014 en el Programa Presupuestal 016 
TBC –VIH/SIDA.
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Objectives: The objective of study is to measure the cost of illness (out of 
pocket costs paid by patients) for T.B in Quetta city, Pakistan. MethOds: Cross 
sectional study was performed on TB patient in Fatima Jinnah chest hospi-
tal Quetta. The TB patients who were registered in hospital were interviewed 
to determine the out of pocket cost paid by TB patients by using standardized 
data collection tool. The descriptive statistics was used to present the data. All 
analyses were performed using SPSS 20.0. Results: The total of 70 TB patients 
were agree to participate in the study. Majority (62%, n= 44) were females with 
rural residency 51.4%, n= 36). Majority of patients had monthly income were 
8000-15000. The total average out of pocket cost was Pk. Rs. 11,685 per month 
for an individual patient. In addition, it was calculated that a patient spend Pk. 
Rs. 292 for diagnostic tests including chest x-ray, additional medicine purchased 
were of Pk. Rs. 1465, travel cost were Pk. Rs. 3,485 , special food cost were Pk. 
Rs. 2,128 rupees accommodation cost were Pk. Rs. 3,825 rupees, & the other 
cost were Pk. Rs. 490. It is worth mentioning here that all the medication and 
other treatment cost is paid by the government. cOnclusiOns: The study con-
cluded that although government paid all the medication and other treatment 
cost for TB patients, yet patient had to bear a high amount of money from his 
pocket which put additional burden to the poor patient suffering with a disease 
like TB.
12.5 million). cOnclusiOns: Colombian decision makers in health could largely 
benefit by controlling relapses for these types of patients. This study is one of the 
first approaches at quantifying the impact of the disease and its relapse. Policy 
measures should consider this data for addressing mental health in a systematic 
and conjoint approach.
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Objectives: 1. To study health effect of smoking by questionnaires and tests. 
2. To study by comparing smoking population’s function of the lung with non-
smoker’s function of the lung. MethOds: 1201 people has participated for the 
research study and they were 20-39 years of age, and older than 40 years old, also 
study has taken in Ulaanbaatar at the same time. Research study included 79 
questions from “Adult core questionnaire” study of chronic respiratory diseases 
in the Asia-Pacific and spirometer analysis has done too. Results: The smok-
ing population by age and gender in Ulaanbaatar. AGE Male Smoking/%/ Female 
Smoking/%/ 20-29 194 75.5 161 19.4 30-39 121 79.3 134 28.4 40-49 153 78.4 152 
24.4 cOnclusiOns: Research study shows that 49.4% of total population and 
76.9% of males, 21.4% of females have been smoking for their lives with some 
circumstances in Ulaanbaatar. Also study shows that 30-39 years old, 70 years 
old females are smoking more than other ages particularly. For males smoking is 
in equal level for all ages. Function of lungs has changed depending on smoking 
and total years of smoking.
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fluticasone ProPionate versus buDesoniDe or becloMetHasone as 
MonotHeraPY treatMent for astHMa Patients - a sYsteMatic review
Saturnino LT, Salgado JB, Penha MF
GlaxoSmithkline, rio de janeiro, Brazil
Objectives: compare the efficacy and the safety of fluticasone propionate in the 
management of moderate to severe asthma in adults and children to the inhaled 
corticosteroids currently available in the public health care system in order to 
present an alternative therapy to the Brazilian government. MethOds: a sys-
tematic review of the MEDLINE, the Cochrane Library and Centre for Reviews and 
Dissemination (CRD) databases was conducted until September 2014, including 
randomized clinical study and systematic reviews about comparison between flu-
ticasone propionate and budesonide or beclomethasone, not associated with other 
medications. There was no age limit and the assessed endpoint was pulmonary 
function through morning and evening Peak Expiratory Flow Rate, Forced Expiratory 
Volume in one second, exacerbation and adverse events. The quality of the stud-
ies was measured by Grades of Recommendation, Assessment, Development and 
Evaluation. Results: there were 788 articles identified in MEDLINE, 231 in The 
Cochrane library and 46 in CRD, among all of these, 259 were duplicates, remaining 
806 to title analysis. In the final analysis, 21 articles were included – 3 system-
atic reviews and 18 randomized clinical studies. All systematic reviews showed a 
strong recommendation in favor of the new technology and high methodological 
quality. Among the clinical studies, 9 of them compared fluticasone propionate 
to beclomethasone and the others 9 to budesonide. The study results showed no 
statistically significant difference between the compared medicines. According to 
the results, fluticasone propionate is effective and well tolerated for the treatment 
of moderate to severe asthma, in adults and children, as well as beclomethasone 
and budesonide. cOnclusiOns: from this perspective, the inclusion of fluticasone 
propionate in the Brazilian Clinical Protocol and Therapeutic Guidelines could rep-
resent an extension of the therapeutic arsenal, especially, for the pediatric popula-
tion that have few options of treatment. Funding for this study was provided by 
GlaxoSmithKline, study HO-14-15763.
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Objectives: Non infectious chronic diseases become one of the most frequent 
cause of morbidity all around the world and they are results of interactions 
between man and his environment. This group of diseases includes also chronic 
obstructive pulmonary disease (COPD), which explains why medications for the 
treatment of this disease take a large part in the consumption. The aim of this 
study was to analyze the consumption of medications in COPD in Serbia and 
in Norway in period from 2007 to 2012. MethOds: The data about the use of 
medications in Serbia were taken from the Agency for Drugs and Medical Devices 
of the Republic of Serbia. The data about the use of medications in Norwey were 
taken from official website of the Norwegian healthcare system. Results: Total 
consumption of medications for the treatment of respiratory diseases in Serbia 
from 2007 to 2012 was lower than the comnsumption of the same medications in 
Norway in the same time of period. The utilized medications of R group in both 
countries was very uneven in this period of time. Between the subgroups, the most 
frequently used medications were those for the chronic obstructive pulmonary 
disease (R03). cOnclusiOns: The consumption of medications in Serbia from 
2007 to 2012 was higher than in Norway. While analysing the consumption of 
medications we can make conclusion that the structure of the utilized medica-
tions in Serbia is not appropriate and is not similar to the farmacoterapeutic 
practice in well developed Norway. This research was supported by Provincial 
